Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALK inhibitors
Pharma
Merck's GLP-1 play; Astellas' AAV deal—Fierce Pharma Asia
Merck licensed an oral GLP-1 from Hansoh. Astellas tapped Sangamo's brain-penetrating AAV. Betta's lung cancer med won an FDA approval. And more.
Angus Liu
Dec 20, 2024 8:51am
China-made lung cancer drug plays catch-up with Pfizer, Roche
Dec 19, 2024 10:20am
Roche's Alecensa snags FDA postsurgery nod in lung cancer
Apr 19, 2024 11:03am
ESMO: Roche's Alecensa cuts postsurgery lung cancer recurrence
Oct 21, 2023 10:30am
Alecensa gives Roche another win in early-stage lung cancer
Sep 1, 2023 10:36am
Pfizer gains its fourth FDA approval for an ALK-positive tumors
Jul 15, 2022 10:49am
